The Power of Time in Range: Revolutionizing Type 1 Diabetes Management Through Continuous Glucose Monitoring

Individuals living with type 1 diabetes (T1D) are engaged in a constant, vigilant effort to manage their blood glucose levels. This meticulous oversight, encompassing both day and night, is crucial for preventing the dangerous extremes of hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar). While traditional finger-prick testing has been the cornerstone of this monitoring for decades, a significant technological leap has occurred with the widespread adoption of continuous glucose monitors (CGMs). These sophisticated wearable devices are not merely tools for immediate data acquisition; they are transforming the landscape of T1D management by providing a comprehensive, nuanced understanding of glucose fluctuations, with "Time in Range" (TIR) emerging as a pivotal metric.

The evolution of diabetes management has been intrinsically linked to technological advancements. For much of the 20th century, managing T1D relied heavily on intermittent blood glucose readings obtained through finger pricks, alongside HbA1c tests that offered a retrospective look at average glucose control over two to three months. While these methods provided essential information, they often failed to capture the dynamic, day-to-day variations in glucose levels that can significantly impact an individual’s health and quality of life. The advent of CGMs marked a paradigm shift, offering real-time data, trend arrows, and customizable alerts that empower individuals and their healthcare teams with unprecedented insights.

CGMs, typically worn on the body, continuously measure glucose levels in the interstitial fluid every one to five minutes. This constant stream of data allows individuals with T1D to make informed decisions in real-time, whether it’s adjusting insulin doses, consuming carbohydrates, or taking other immediate actions to maintain glucose within a safe and healthy window. Beyond immediate interventions, the wealth of data generated by CGMs facilitates the identification of long-term patterns and trends, which are invaluable for refining personalized diabetes management strategies. Integrated with connected smartphone applications, CGMs can generate detailed reports, presenting a holistic view of glucose trends that extends beyond simple average readings to include critical metrics like Time in Range. This article delves into the significance of Time in Range, exploring its definition, importance, and future applications in the ongoing quest for optimal T1D management.

Understanding Time in Range: A Deeper Dive

Time in Range (TIR) is defined as the percentage of time an individual’s blood glucose levels remain within a specified target range. For most individuals with T1D, this target range is clinically recognized as 70 to 180 milligrams of glucose per deciliter of blood (mg/dL). This metric moves beyond the singular focus on average glucose levels, as represented by HbA1c, to provide a more granular understanding of glucose variability and stability.

Current clinical guidelines and standards of care, as established by leading diabetes organizations, recommend specific targets for individuals with T1D to aim for when utilizing CGM technology. These targets offer a framework for evaluating glucose control:

These percentages represent aspirational goals, acknowledging that individual glucose targets can vary significantly. Factors such as the duration of T1D diagnosis, age, presence of diabetes-related complications, experience with hypoglycemia unawareness, pregnancy status, and other co-existing health conditions necessitate a personalized approach. Therefore, close collaboration between individuals with T1D and their healthcare teams is paramount. This partnership ensures that CGM data is thoroughly reviewed, and that personalized high and low glucose alerts are configured appropriately to reflect individual needs and risk profiles.

The visual representation of glucose data provided by CGMs is instrumental. Twenty-four-hour graphs illustrate glucose levels throughout the day and night, clearly delineating periods spent within range, above range, and below range. These graphs, often reviewed over a 14-day period to identify consistent patterns, are particularly effective in pinpointing how specific times of day, dietary intake, physical activity, or other external factors influence glucose excursions. The figure below, for instance, demonstrates how different patterns of time spent above, in, and below range can coexist with the same average glucose level, underscoring why TIR offers a more complete picture than average glucose alone.

[Insert Image: A graphic illustrating 24-hour glucose trends from a CGM, showing periods in, above, and below target ranges. The caption should explain that different percentages of time spent in, above, or below range can correlate with the same average glucose level, highlighting the importance of TIR for a comprehensive view of glucose trends.]

Time in Range Versus HbA1c: Complementary Metrics for Comprehensive Care

While HbA1c has long served as the gold standard for assessing long-term glycemic control, its limitations in capturing glucose variability are well-documented. HbA1c provides a retrospective average, essentially a snapshot of average blood sugar over the preceding 2-3 months. It does not reveal the frequency or duration of potentially dangerous high or low blood sugar episodes. In contrast, TIR, derived from CGM data, offers a dynamic, real-time perspective on glucose fluctuations.

The synergy between TIR and HbA1c is crucial for informed clinical decision-making. Healthcare professionals utilize both metrics to construct a comprehensive understanding of an individual’s glycemic control. While HbA1c offers a broad overview of average glucose levels, TIR provides the critical detail of how consistently those levels are maintained within a healthy range. This dual approach allows for more precise treatment adjustments and a better assessment of complication risk.

The importance of TIR extends beyond individual patient care. It has become an increasingly significant outcome measure in clinical trials, particularly for evaluating the efficacy of new diabetes therapies and technologies. By demonstrating improvements in TIR, researchers can provide robust evidence that a particular intervention is not only lowering average blood sugar but also enhancing glycemic stability, a key factor in mitigating the long-term health consequences of diabetes.

The Significance of Time in Range in T1D Management

The primary advantage of TIR, and CGM data more broadly, lies in its ability to offer individuals with T1D an extensive overview of the factors influencing their glucose levels throughout the day. A complex interplay of lifestyle choices, physiological responses, and external influences—including exercise, meals, stress, hormonal fluctuations (such as those associated with menstrual cycles), and illness—can dramatically impact blood sugar. TIR provides a tangible metric to understand how these elements affect personal glucose management.

Dr. Brynn E. Marks, Senior Director of Medical Affairs at Breakthrough T1D, emphasizes this point: "Time in range helps people with T1D better understand glucose patterns that are not captured by HbA1c. Additionally, CGM can help people to review their glucose patterns in between visits with their diabetes team and allow for more frequent adjustments to their insulin doses. Reviewing and acting on time in range data and glucose patterns identified by CGM can empower people to manage their T1D and to avoid the roller coasters of managing high and low blood glucose that negatively impact quality of life."

Emerging research strongly associates higher TIR with a reduced risk of developing diabetes-related complications. While the precise causal links are still under investigation, the consistent maintenance of glucose levels within the target range is believed to protect against the microvascular and macrovascular damage that can arise from chronic hyperglycemia. Consequently, TIR is not only a marker of good control but also a potential predictor of long-term health outcomes. As our understanding of this metric deepens, its application in both clinical practice and research is expected to expand significantly.

The Future of Time in Range: Emerging Horizons

The field of diabetes technology and therapy is in a state of rapid evolution, and the concept of Time in Range is at the forefront of these advancements. Several key areas are poised to further enhance its utility and impact.

Time in Tight Range: A Narrower Focus

Building upon the concept of Time in Range, "Time in Tight Range" (TITR) is emerging as a promising metric. TITR specifically measures the percentage of time glucose levels are maintained within a narrower window, typically between 70 and 140 mg/dL. This range more closely approximates the glycemic control observed in individuals without diabetes, who typically spend approximately 96% of their time within this tight physiological window.

Researchers are exploring the hypothesis that fluctuations outside this tighter range, even if still within the broader 70-180 mg/dL TIR, may be a more sensitive predictor of complication risk. However, integrating TITR into routine clinical decision-making requires further research to establish its definitive benefits and to develop therapies and technologies that enable individuals with T1D to achieve this narrower target without imposing undue burdens or increasing the risk of hypoglycemia.

Automated Insulin Delivery Systems in Clinical Trials

Automated Insulin Delivery (AID) systems represent a significant stride in T1D management. These sophisticated systems, often referred to as artificial pancreas technology, leverage CGM data to automatically adjust insulin delivery. Current AID systems can increase or decrease basal insulin rates in response to glucose trends, thereby improving TIR and TITR while reducing both high and low blood sugar events. However, most existing systems still require meal announcements from the user to deliver bolus insulin.

The next frontier in AID technology involves fully closed-loop systems, which aim to eliminate the need for manual meal announcements. These advanced systems hold the potential to further optimize glycemic control, allowing individuals to achieve target TIR and TITR with even less manual intervention. Breakthrough T1D is actively supporting research initiatives focused on developing and validating these next-generation AID systems, with the goal of bringing them to the T1D community safely and swiftly.

Non-Insulin Therapies: Expanding the Treatment Arsenal

While insulin remains the cornerstone of T1D treatment, research is increasingly exploring the role of non-insulin therapies that can complement insulin therapy and AID systems. These adjunctive treatments aim to address various aspects of metabolic health, including insulin resistance, weight management, hypoglycemia prevention, and the mitigation of long-term complications.

Breakthrough T1D is actively funding studies investigating a range of non-insulin therapies. The objective is to develop a diversified treatment landscape, offering individuals with T1D a wider array of options tailored to their specific needs and metabolic profiles. This personalized approach seeks to optimize not only blood sugar management but also overall health and well-being.

GLP-1 Receptor Agonists in Clinical Trials: A Promising Avenue

A notable example of non-insulin therapy research is the investigation of GLP-1 receptor agonists. The ADJUST-T1D clinical trial, supported by Breakthrough T1D, provided compelling evidence for the benefits of semaglutide (a GLP-1 receptor agonist, marketed as Ozempic) in adults with T1D who are also overweight or obese. The study demonstrated that treatment with semaglutide led to significant improvements in both time in range and time in tight range compared to a placebo group over a 26-week period. Furthermore, participants on semaglutide experienced notable improvements in weight management.

This trial’s findings suggest that GLP-1 receptor agonists could play a valuable role in the comprehensive management of T1D, particularly for individuals managing additional metabolic challenges. Breakthrough T1D continues to champion research in this area, aiming to further elucidate the potential of this drug class for the broader T1D community.

The Path Forward: Accessibility and Standardization

Despite the remarkable advancements in CGM technology and the growing evidence supporting the benefits of TIR, many individuals with T1D still struggle to consistently achieve their target ranges. Factors such as the cost and accessibility of advanced technologies, along with the availability of effective non-insulin therapies, can create barriers to optimal glucose management.

The ultimate goal is to make technologies and therapies that facilitate the achievement of target TIR universally accessible. As these advancements become more widespread, the metric of Time in Tight Range may transition from an aspirational goal to a more widely adopted standard of care. However, it is crucial to acknowledge that glycemic targets are inherently personalized. Further research is necessary to identify specific patient populations that would benefit most from focusing on TITR.

In the interim, Breakthrough T1D remains dedicated to its mission: improving the lives of the T1D community today while accelerating the pace toward cures. This dual focus involves optimizing current management strategies with available tools and technologies, while simultaneously driving innovation through research and advocacy to ensure that the next generation of breakthroughs is rapidly developed and implemented.

Expert Insights on the Future of Time in Range

Jonathan Rosen, Ph.D., Director of Research at Breakthrough T1D, offers a forward-looking perspective: "In the future, I think we will see greater use of time in range in T1D management by people with T1D and care providers as adoption of CGM continues to increase. A growing body of evidence suggests that greater time in range, like low HbA1c, is associated with a lower risk of developing long-term complications. These data might not only support CGM use and attention to time in range in clinical decision-making, but may also impact the way new therapies are evaluated. Today, time in range is widely accepted as a means to evaluate AID systems, but we are not there yet when it comes to evaluating new drugs. Finally, there is a lot of ongoing research to understand time in tight range and how this will help us with clinical guidance and therapy development in the future."

Breakthrough T1D’s Commitment to Improving Lives

The Improving Lives Program at Breakthrough T1D is fundamentally committed to ensuring that individuals living with T1D experience the highest possible quality of life while the pursuit of cures continues. This commitment translates into active support for research aimed at driving innovation in diabetes technology and devices. Simultaneously, the organization investigates how both new and repurposed medications can enhance blood sugar control, reduce the risk of long-term complications, and promote overall metabolic health.

Beyond research, Breakthrough T1D actively engages in advocacy work to streamline approval and coverage pathways for these vital advancements. By enhancing the clinical adoption of devices and therapies, the organization seeks to improve blood sugar management for a greater number of individuals than ever before. Until definitive cures are widely available, Breakthrough T1D remains steadfast in its mission to improve the lives of those currently living with type 1 diabetes.

Written by: Sandy Vogt, Ph.D.